It’s time to beat cancer
Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.
We are building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). We believe that by reprogramming the TIME, we can significantly improve cancer treatment outcomes.
OUR APPROACH
Vigeo is currently developing therapies that target the TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumorigenic protein, and one of the body’s own defenses against cancer. Tsp-1 has been shown to attack cancer cells and to prevent their spread through metastasis via CD36 and CD47 pathways.
Our clinical
trials
We are currently studying VT1021, a peptide therapeutic agent in clinical trials enrolling patients in pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high amounts of CD36.
Latest News
July 06, 2022
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM Agile Trial
January 20, 2022
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma
November 16, 2021